Follow-up validation of the pre-clinically defined surface fingerprint in a cohort of PCa patient samples resulted in a 6-molecule surface fingerprint composed of EpCAM, CD9, CD44, CD59, CD95, and SSEA-4. This evidence concerns the gene CD9 and posterior cortical atrophy.